We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q4
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) reported fourth-quarter 2020 adjusted earnings per share (EPS) of 98 cents, which surpassed the Zacks Consensus Estimate of 87 cents by 12.6%. The figure also improved 7.6% from the year-ago quarter.
Further for 2020, adjusted EPS came in at $3.60, beating the Zacks Consensus Estimate by 3.2%.The bottom line also grew 11.8% year over year.
Revenues
For the fourth quarter, total revenues (including Royalty and other revenues) improved 19.2% year over year to $295.1 million and beat the Zacks Consensus Estimate by 1.9% as well.
Moreover, for 2020, revenues came in at $1.14 billion, up 22% year over year. Meanwhile, the topline was in line with the Zacks Consensus Estimate.
Segmental Analysis
Product Revenues
Product revenues in the fourth quarter totaled $295.1 million, up 19.2% from the year-ago quarter and 18.1% at constant currency (cc).
Per management, shipments of non-invasive technology boards and instruments (excluding handheld and fingertip pulse oximeters) surged 35.2% to 83,000 in the quarter.
Margin Analysis
In the quarter under review, gross profit totaled $186.9 million, up 11.9% year over year. Gross margin was 63.4%, down 409 basis points (bps).
Total operating costs came in at $122 million, up 15.8%.
Operating profit in the quarter totaled $64.9 million, up 5.4% from the year-ago level. Operating margin contracted 288 bps to 21.9% in the quarter.
Masimo Corporation Price, Consensus and EPS Surprise
The company exited the fourth quarter of 2020 with cash and cash equivalents of $641.4 million compared with $567.7 million at the end of the year-ago period. Cumulative net cash provided by operating activities came in at $210.9 million compared with $221.6 million in the year-ago period.
2021 Guidance
Total revenues are projected at $1.20 billion. The Zacks Consensus Estimate for the metric is pegged at $1.20 billion. Adjusted EPS is projected at $3.80. The Zacks Consensus Estimate for the same is pegged at $3.76.
In Conclusion
Masimo exited the fourth quarter on a strong note. The company continues to gain from its key Product segment, which witnessed solid growth in the quarter under review. The company’s non-invasive technology shipments also surged in the quarter. In fact, management foresees increased shipments for the quarters ahead.The recent launch of the Masimo SafetyNet, designed to help fight the coronavirus pandemic, continues to buoy optimism. The outbreak boosted demand for the company’s products among the direct and OEM customers.
On the flip side, contraction of both margins is a concern. Masimo’s Royalty and Other segment saw no contribution during the quarter. Further, the company faces fierce competition from the MedTech bigwigs.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. The Zacks Consensus Estimate was of a loss per share of two cents. Additionally, revenues of $72.8 million beat the consensus mark by 8%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Masimo (MASI) Earnings and Revenues Beat Estimates in Q4
Masimo Corporation (MASI - Free Report) reported fourth-quarter 2020 adjusted earnings per share (EPS) of 98 cents, which surpassed the Zacks Consensus Estimate of 87 cents by 12.6%. The figure also improved 7.6% from the year-ago quarter.
Further for 2020, adjusted EPS came in at $3.60, beating the Zacks Consensus Estimate by 3.2%.The bottom line also grew 11.8% year over year.
Revenues
For the fourth quarter, total revenues (including Royalty and other revenues) improved 19.2% year over year to $295.1 million and beat the Zacks Consensus Estimate by 1.9% as well.
Moreover, for 2020, revenues came in at $1.14 billion, up 22% year over year. Meanwhile, the topline was in line with the Zacks Consensus Estimate.
Segmental Analysis
Product Revenues
Product revenues in the fourth quarter totaled $295.1 million, up 19.2% from the year-ago quarter and 18.1% at constant currency (cc).
Per management, shipments of non-invasive technology boards and instruments (excluding handheld and fingertip pulse oximeters) surged 35.2% to 83,000 in the quarter.
Margin Analysis
In the quarter under review, gross profit totaled $186.9 million, up 11.9% year over year. Gross margin was 63.4%, down 409 basis points (bps).
Total operating costs came in at $122 million, up 15.8%.
Operating profit in the quarter totaled $64.9 million, up 5.4% from the year-ago level. Operating margin contracted 288 bps to 21.9% in the quarter.
Masimo Corporation Price, Consensus and EPS Surprise
Masimo Corporation price-consensus-eps-surprise-chart | Masimo Corporation Quote
Cash Position
The company exited the fourth quarter of 2020 with cash and cash equivalents of $641.4 million compared with $567.7 million at the end of the year-ago period. Cumulative net cash provided by operating activities came in at $210.9 million compared with $221.6 million in the year-ago period.
2021 Guidance
Total revenues are projected at $1.20 billion. The Zacks Consensus Estimate for the metric is pegged at $1.20 billion. Adjusted EPS is projected at $3.80. The Zacks Consensus Estimate for the same is pegged at $3.76.
In Conclusion
Masimo exited the fourth quarter on a strong note. The company continues to gain from its key Product segment, which witnessed solid growth in the quarter under review. The company’s non-invasive technology shipments also surged in the quarter. In fact, management foresees increased shipments for the quarters ahead.The recent launch of the Masimo SafetyNet, designed to help fight the coronavirus pandemic, continues to buoy optimism. The outbreak boosted demand for the company’s products among the direct and OEM customers.
On the flip side, contraction of both margins is a concern. Masimo’s Royalty and Other segment saw no contribution during the quarter. Further, the company faces fierce competition from the MedTech bigwigs.
Zacks Rank & Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that already announced quarterly results are Hologic, Inc. (HOLX - Free Report) , Abbott Laboratories (ABT - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) , each presently carrying a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1Rank (Strong Buy) stocks here.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. The Zacks Consensus Estimate was of a loss per share of two cents. Additionally, revenues of $72.8 million beat the consensus mark by 8%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>